Dr Claire von Mollendorf is a medical epidemiologist currently working as a senior research fellow in the New Vaccines and Asia-Pacific Research Groups at the Murdoch Children’s Research Unit (MCRI). She has been with MCRI since 2017 and is an investigator on a number of projects in Mongolia. She is also the co-principal investigator on a Coalition for Epidemic Preparedness Innovations (CEPI) funded COVID-19 vaccine booster study. Dr von Mollendorf has an honorary appointment as a Senior Fellow within the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Department of Paediatrics.
Dr von Mollendorf is the project manager for a National Health & Medical Research Council Centre of Research Excellence for Pneumococcal Disease Control in the Asia-Pacific (CRE-PDC) which aims to address research gaps related to pneumococcal conjugate vaccine use in the Asia-Pacific region. It also focuses on building research and leadership capacity for early career researchers in the region.
Prior to 2017 she worked in different research areas, including women's health, HIV and pneumococcal research, in South Africa. Her passion and involvement in research has spanned over an 20 year period and has included adults and children, some vulnerable groups and ranged from clinical trials to observational studies. She also has an interest in the impact of environmental pollution on health.
Dr Claire von Mollendorf is a medical epidemiologist currently working as a senior research fellow in the New Vaccines and Asia-Pacific Research Groups at the Murdoch Children’s Research Unit (MCRI). She has been with MCRI since 2017 and is an...
Dr Claire von Mollendorf is a medical epidemiologist currently working as a senior research fellow in the New Vaccines and Asia-Pacific Research Groups at the Murdoch Children’s Research Unit (MCRI). She has been with MCRI since 2017 and is an investigator on a number of projects in Mongolia. She is also the co-principal investigator on a Coalition for Epidemic Preparedness Innovations (CEPI) funded COVID-19 vaccine booster study. Dr von Mollendorf has an honorary appointment as a Senior Fellow within the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Department of Paediatrics.
Dr von Mollendorf is the project manager for a National Health & Medical Research Council Centre of Research Excellence for Pneumococcal Disease Control in the Asia-Pacific (CRE-PDC) which aims to address research gaps related to pneumococcal conjugate vaccine use in the Asia-Pacific region. It also focuses on building research and leadership capacity for early career researchers in the region.
Prior to 2017 she worked in different research areas, including women's health, HIV and pneumococcal research, in South Africa. Her passion and involvement in research has spanned over an 20 year period and has included adults and children, some vulnerable groups and ranged from clinical trials to observational studies. She also has an interest in the impact of environmental pollution on health.
Top Publications
Dunne, EM, Cilloniz, C, von Mollendorf, C, Lewnard, J, Grant, LR, Slack, MPE, Jodar, L, Theilacker, C, Gessner, BD.
Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?.
Arch Bronconeumol
59(3)
:
157 -164
2023
view publication
Wilkes, C, Bava, M, Graham, HR, Duke, T, ARI Review group.
What are the risk factors for death among children with pneumonia in low- and middle-income countries? A systematic review..
J Glob Health
13:
05003
2023
view publication
Reyburn, R, Maher, J, von Mollendorf, C, Gwee, A, Mulholland, K, Russell, F, ARI Review group.
The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: A systematic literature review..
J Glob Health
13:
05001
2023
view publication
Reyburn, R, Tsatsaronis, A, von Mollendorf, C, Mulholland, K, Russell, FM, ARI Review group.
Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old..
J Glob Health
13:
05002
2023
view publication
Fagerli, K, Ulziibayar, M, Suuri, B, Luvsantseren, D, Narangerel, D, Batsaikhan, P, Tsolmon, B, Gessner, BD, Dunne, EM, Grobler, AC, et al.
Epidemiology of pneumonia in hospitalized adults ≥18 years old in four districts of Ulaanbaatar, Mongolia, 2015-2019..
Lancet Reg Health West Pac
30:
100591
2023
view publication